{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:26:54Z","timestamp":1781504814413,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Faculty of Medicine Ramathibodi Hospital, Mahidol University","award":["64004"],"award-info":[{"award-number":["64004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40123-024-01082-y","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T09:03:28Z","timestamp":1734685408000},"page":"363-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04683796","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Passara","family":"Jongkhajornpong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-4581","authenticated-orcid":false,"given":"Kaevalin","family":"Lekhanont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasivimol","family":"Rattanasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapaporn","family":"Pisitkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"1082_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.transci.2017.07.023","volume":"56","author":"G Giannaccare","year":"2017","unstructured":"Giannaccare G, Versura P, Buzzi M, Primavera L, Pellegrini M, Campos EC. Blood-derived eye drops for the treatment of cornea and ocular surface diseases. Transfus Apher Sci. 2017;56:595\u2013604.","journal-title":"Transfus Apher Sci"},{"key":"1082_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/ACI.0000000000000770","volume":"21","author":"D Cui","year":"2021","unstructured":"Cui D, Li G, Akpek EK. Autologous serum eye drops for ocular surface disorders. Curr Opin Allergy Clin Immunol. 2021;21:493\u20139.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1082_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/bjophthalmol-2015-306842","volume":"100","author":"NG Soni","year":"2016","unstructured":"Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol. 2016;100:22\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1082_CR4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.survophthal.2015.03.003","volume":"60","author":"RB Nugent","year":"2015","unstructured":"Nugent RB, Lee GA. Ophthalmic use of blood-derived products. Surv Ophthalmol. 2015;60:406\u201334.","journal-title":"Surv Ophthalmol"},{"key":"1082_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/ICU.0000000000000169","volume":"26","author":"JL Alio","year":"2015","unstructured":"Alio JL, Rodriguez AE, Wr\u00f3belDudzi\u0144ska D. Eye platelet-rich plasma in the treatment of ocular surface disorders. Curr Opin Ophthalmol. 2015;26:325\u201332.","journal-title":"Curr Opin Ophthalmol"},{"key":"1082_CR6","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1111\/aos.12710","volume":"93","author":"E Anitua","year":"2015","unstructured":"Anitua E, Muruzabal F, Tayebba A, et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol. 2015;93:e605\u201314.","journal-title":"Acta Ophthalmol"},{"key":"1082_CR7","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ophtha.2006.10.044","volume":"114","author":"JL Alio","year":"2007","unstructured":"Alio JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007;114:1286-93.e1.","journal-title":"Ophthalmology"},{"key":"1082_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/bioengineering11030209","volume":"11","author":"A Carvalho","year":"2024","unstructured":"Carvalho A, Ferreira AF, Soares M, et al. Optimization of platelet-rich plasma preparation for regenerative medicine: comparison of different anticoagulants and resuspension media. Bioengineering (Basel). 2024;11:209.","journal-title":"Bioengineering (Basel)"},{"key":"1082_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","volume":"88","author":"G Geerling","year":"2004","unstructured":"Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467\u201374.","journal-title":"Br J Ophthalmol"},{"key":"1082_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40123-017-0100-z","volume":"6","author":"JL Alio","year":"2017","unstructured":"Alio JL, Rodriguez AE, Ferreira-Oliveira R, et al. Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional, non-randomized study. Ophthalmol Ther. 2017;6:285\u201393.","journal-title":"Ophthalmol Ther"},{"key":"1082_CR11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s10384-012-0175-y","volume":"56","author":"KM Kim","year":"2012","unstructured":"Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol. 2012;56:544\u201350.","journal-title":"Jpn J Ophthalmol"},{"key":"1082_CR12","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.3390\/jcm12093126","volume":"12","author":"D Wr\u00f3bel-Dudzi\u0144ska","year":"2023","unstructured":"Wr\u00f3bel-Dudzi\u0144ska D, Przekora A, Kazimierczak P, \u0106wikli\u0144ska-Haszcz A, Kosior-Jarecka E, \u017barnowski T. The comparison between the composition of 100% autologous serum and 100% platelet-rich plasma eye drops and their impact on the treatment effectiveness of dry eye disease in primary Sj\u00f6gren syndrome. J Clin Med. 2023;12:3126.","journal-title":"J Clin Med"},{"key":"1082_CR13","doi-asserted-by":"publisher","first-page":"8906","DOI":"10.1038\/s41598-022-12879-x","volume":"12","author":"C Metheetrairut","year":"2022","unstructured":"Metheetrairut C, Ngowyutagon P, Tunganuntarat A, Khowawisetsut L, Kittisares K, Prabhasawat P. Comparison of epitheliotrophic factors in platelet-rich plasma versus autologous serum and their treatment efficacy in dry eye disease. Sci Rep. 2022;12:8906.","journal-title":"Sci Rep"},{"key":"1082_CR14","doi-asserted-by":"publisher","first-page":"e001857","DOI":"10.1136\/bmjophth-2024-001857","volume":"9","author":"P Jongkhajornpong","year":"2024","unstructured":"Jongkhajornpong P, Lekhanont K, Rattanasiri S, et al. Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial. BMJ Open Ophthalmol. 2024;9:e001857.","journal-title":"BMJ Open Ophthalmol"},{"key":"1082_CR15","doi-asserted-by":"crossref","unstructured":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:75\u201392.","DOI":"10.1016\/S1542-0124(12)70081-2"},{"key":"1082_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048479","volume":"11","author":"P Jongkhajornpong","year":"2021","unstructured":"Jongkhajornpong P, Numthavaj P, Anothaisintawee T, et al. Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol. BMJ Open. 2021;11: e048479.","journal-title":"BMJ Open"},{"key":"1082_CR17","doi-asserted-by":"publisher","first-page":"38143","DOI":"10.1038\/srep38143","volume":"6","author":"K Lekhanont","year":"2016","unstructured":"Lekhanont K, Jongkhajornpong P, Anothaisintawee T, Chuckpaiwong V. Undiluted serum eye drops for the treatment of persistent corneal epithelial defects. Sci Rep. 2016;6:38143.","journal-title":"Sci Rep"},{"key":"1082_CR18","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2174\/138920112800624355","volume":"13","author":"JL Alio","year":"2012","unstructured":"Alio JL, Arnalich-Montiel F, Rodriguez AE. The role of \u201ceye platelet-rich plasma\u201d (E-PRP) for wound healing in ophthalmology. Curr Pharm Biotechnol. 2012;13:1257\u201365.","journal-title":"Curr Pharm Biotechnol"},{"key":"1082_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1089\/ten.tec.2011.0308","volume":"18","author":"J Araki","year":"2012","unstructured":"Araki J, Jona M, Eto H, et al. Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen. Tissue Eng Part C Methods. 2012;18:176\u201385.","journal-title":"Tissue Eng Part C Methods"},{"key":"1082_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00417-004-1106-5","volume":"243","author":"L Liu","year":"2005","unstructured":"Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G. An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol. 2005;243:706\u201314.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1082_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/521315","volume":"2013","author":"K Lekhanont","year":"2013","unstructured":"Lekhanont K, Jongkhajornpong P, Choubtum L, Chuckpaiwong V. Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery. Biomed Res Int. 2013;2013: 521315.","journal-title":"Biomed Res Int"},{"key":"1082_CR22","first-page":"55993","volume":"128","author":"PK Balne","year":"2017","unstructured":"Balne PK, Au VB, Tong L, et al. Bead based multiplex assay for analysis of tear cytokine profiles. J Vis Exp. 2017;128:55993.","journal-title":"J Vis Exp"},{"key":"1082_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.farma.2010.02.004","volume":"35","author":"A Jover Botella","year":"2011","unstructured":"Jover Botella A, M\u00e1rquez Peir\u00f3 JF, M\u00e1rques K, Monts Cambero N, Selva OJ. Effectiveness of 100% autologous serum drops in ocular surface disorders. Farm Hosp. 2011;35:8\u201313.","journal-title":"Farm Hosp"},{"key":"1082_CR24","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/archophthalmol.2012.1652","volume":"130","author":"CA Dalmon","year":"2012","unstructured":"Dalmon CA, Chandra NS, Jeng BH. Use of autologous serum eye drops for the treatment of ocular surface disease: first US experience in a large population as an insurance-covered benefit. Arch Ophthalmol. 2012;130:1612\u20133.","journal-title":"Arch Ophthalmol"},{"key":"1082_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/02713683.2012.720340","volume":"38","author":"YK Cho","year":"2013","unstructured":"Cho YK, Huang W, Kim GY, Lim BS. Comparison of autologous serum eye drops with different diluents. Curr Eye Res. 2013;38:9\u201317.","journal-title":"Curr Eye Res"},{"key":"1082_CR26","first-page":"322","volume":"101","author":"V Tahmaz","year":"2017","unstructured":"Tahmaz V, Gehlsen U, Sauerbier L, et al. Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. Br J Ophthalmol. 2017;101:322\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1082_CR27","first-page":"CD009327","volume":"2","author":"Q Pan","year":"2017","unstructured":"Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;2:CD009327.","journal-title":"Cochrane Database Syst Rev"},{"key":"1082_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/OPX.0000000000002042","volume":"100","author":"NG Quan","year":"2023","unstructured":"Quan NG, Leslie L, Li T. Autologous serum eye drops for dry eye: systematic review. Optom Vis Sci. 2023;100:564\u201371.","journal-title":"Optom Vis Sci"},{"key":"1082_CR29","first-page":"200","volume":"17","author":"M Franchini","year":"2019","unstructured":"Franchini M, Cruciani M, Mengoli C, et al. Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis. Blood Transfus. 2019;17:200\u20139.","journal-title":"Blood Transfus"},{"key":"1082_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211212","volume":"14","author":"S Meybosch","year":"2019","unstructured":"Meybosch S, De Monie A, Ann\u00e9 C, et al. Epidermal growth factor and its influencing variables in healthy children and adults. PLoS\u00a0One. 2019;14: e0211212.","journal-title":"PLoS\u00a0One"},{"key":"1082_CR31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.7205\/MILMED-D-13-00336","volume":"179","author":"JR Evanson","year":"2014","unstructured":"Evanson JR, Guyton MK, Oliver DL, et al. Gender and age differences in growth factor concentrations from platelet-rich plasma in adults. Mil Med. 2014;179:799\u2013805.","journal-title":"Mil Med"},{"key":"1082_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40634-019-0175-7","volume":"6","author":"Y Taniguchi","year":"2019","unstructured":"Taniguchi Y, Yoshioka T, Sugaya H, et al. Growth factor levels in leukocyte-poor platelet-rich plasma and correlations with donor age, gender, and platelets in the Japanese population. J Exp Orthop. 2019;6:4.","journal-title":"J Exp Orthop"},{"key":"1082_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.9.6.22","volume":"9","author":"AE Rodriguez","year":"2020","unstructured":"Rodriguez AE, Gisbert S, Palaz\u00f3n A, Alio JL. Quantification of growth factors and fibronectin in diverse preparations of platelet-rich plasma for the treatment of ocular surface disorders (E-PRP). Transl Vis Sci Technol. 2020;9:22.","journal-title":"Transl Vis Sci Technol"},{"key":"1082_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40778-016-0034-8","volume":"2","author":"EA Masoudi","year":"2016","unstructured":"Masoudi EA, Ribas J, Kaushik G, Leijten J, Khademhosseini A. Platelet-rich blood derivatives for stem cell-based tissue engineering and regeneration. Curr Stem Cell Rep. 2016;2:33\u201342.","journal-title":"Curr Stem Cell Rep"},{"key":"1082_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11306-016-1109-3","volume":"12","author":"D Lesche","year":"2016","unstructured":"Lesche D, Geyer R, Lienhard D, et al. Does centrifugation matter? Centrifugal force and spinning time alter the plasma metabolome. Metabolomics. 2016;12:159.","journal-title":"Metabolomics"},{"key":"1082_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.598816","volume":"8","author":"DV Pachito","year":"2020","unstructured":"Pachito DV, Bagattini \u00c2M, de Almeida AM, Mendrone-J\u00fanior A, Riera R. Technical procedures for preparation and administration of platelet-rich plasma and related products: a scoping review. Front Cell Dev Biol. 2020;8: 598816.","journal-title":"Front Cell Dev Biol"},{"key":"1082_CR37","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1515\/CCLM.2008.170","volume":"46","author":"G Lippi","year":"2008","unstructured":"Lippi G, Blanckaert N, Bonini P, et al. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med. 2008;46:764\u201372.","journal-title":"Clin Chem Lab Med"},{"key":"1082_CR38","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/gerona\/63.8.879","volume":"63","author":"SX Leng","year":"2008","unstructured":"Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci. 2008;63:879\u201384.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1082_CR39","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.3390\/cells12232730","volume":"12","author":"KE Tarvestad-Laise","year":"2023","unstructured":"Tarvestad-Laise KE, Ceresa BP. Modulating growth factor receptor signaling to promote corneal epithelial homeostasis. Cells. 2023;12:2730.","journal-title":"Cells"},{"key":"1082_CR40","doi-asserted-by":"publisher","first-page":"DES151","DOI":"10.1167\/iovs.17-23623","volume":"59","author":"Y Hori","year":"2018","unstructured":"Hori Y. Secreted mucins on the ocular surface. Investig Ophthalmol Vis Sci. 2018;59:DES151\u20136.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1082_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4103\/tjo.tjo_102_17","volume":"7","author":"IH Ma","year":"2017","unstructured":"Ma IH, Chen LW, Tu WH, Lu CJ, Huang CJ, Chen WL. Serum components and clinical efficacies of autologous serum eye drops in dry eye patients with active and inactive Sj\u00f6gren syndrome. Taiwan J Ophthalmol. 2017;7:213\u201320.","journal-title":"Taiwan J Ophthalmol"},{"key":"1082_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtos.2020.02.011","volume":"18","author":"M Ripa","year":"2020","unstructured":"Ripa M, Jabbehdari S, Yazdanpanah G, et al. The role of multisystem disease in composition of autologous serum tears and ocular surface symptom improvement. Ocul Surf. 2020;18:499\u2013504.","journal-title":"Ocul Surf"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-01082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-01082-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-01082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T16:01:54Z","timestamp":1737561714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-01082-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-01082-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Passara Jongkhajornpong, Kaevalin Lekhanont, Sasivimol Rattanasiri, Prapaporn Pisitkun, and Ammarin Thakkinstian have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Ethics committee of Ramathibodi Hospital, Mahidol University (No. MURA2022\/415) and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants before study enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}